Entries by circlek

2018 Operational Update

Tim Edwards appointed as Executive Chairman KA2237 and KA2507 – innovative, molecular-targeted anti-cancer therapeutics – progressing in Phase I clinical trials for the treatment of cancer, with clinical responses confirmed for KA2237 in patients with refractory B-cell lymphomas Research and development activities on a novel, differentiated HDAC6 inhibitor series progressing well, with preclinical development candidate […]